Single-Agent Epirubicin as Primary Chemotherapy in T2–T3, N0–N2, M0 Breast Carcinoma: 6-Year Follow-Up

Publisher： Karger

E-ISSN： 1423-0232|67|1|40-47

ISSN： 0030-2414

Source： Oncology, Vol.67, Iss.1, 2004-10, pp. : 40-47

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adjuvant Chemotherapy in the Management of pT3N0M0 Transitional Cell Carcinoma of the Upper Urinary Tract

By  

Urologia Internationalis, Vol. 77, Iss. 1, 2009-05 ,pp. : 22-26

Karger

Access to resources Recommend Favorite

Schmincke’s Tumor, Carcinoma of the Base of the Tongue c T1-2, cN2c M0 – A Case Report

By  

Case Reports in Oncology, Vol. 3, Iss. 1, 2010-03 ,pp. : 77-82

Karger

Access to resources Recommend Favorite

Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States

By  

Oncology, Vol. 93, Iss. 4, 2017-07 ,pp. : 233-242

Karger

Access to resources Recommend Favorite

A Phase I Study of Concurrent Chemoradiotherapy with S-1 for T2N0 Glottic Carcinoma

By  

Oncology, Vol. 71, Iss. 5-6, 2007-09 ,pp. : 369-373

Karger

Access to resources Recommend Favorite

Poor prognostic subgroup in T3N0 stage IIA gastric cancer, suggesting an indication for adjuvant chemotherapy

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 111, Iss. 2, 2015-02 ,pp. : 221-225

John Wiley & Sons Inc

Access to resources Recommend Favorite